Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ruxoprubart by NovelMed Therapeutics for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Ruxoprubart is under clinical development by NovelMed Therapeutics and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData,...